Literature DB >> 9797717

Deposition of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat.

M Sun1, M Yokoyama, T Ishiwata, G Asano.   

Abstract

Advanced glycation end products (AGE) in tissues are important for the central pathological features of diabetic complication. Although AGE bind to several cell-surface sites, resulting in altered cellular functions, receptor for AGE (RAGE) appears to have a central role. We examined AGE accumulation and RAGE expression in the aorta and heart of rats with streptozotocin (STZ)-induced diabetes, 0, 4, 8, 12, 16 and 24 weeks after STZ administration. Early atherosclerotic findings in the intima and medial thinning were observed in the aorta after 16 weeks of STZ-Induced diabetes. Immunohistochemistry and microscope spectrophotometry showed that AGE deposition increased significantly in the aorta and vessels of the myocardium, depending on the period of hyperglycaemia. RAGE was expressed in the endothelial cells and vascular smooth muscle cells of all animals. The number of smooth muscle cells with RAGE immunoreactivity increased until 12 weeks after STZ injection, and then decreased in rats with diabetes between 16 and 24 weeks. On the other hand, total RAGE mRNA levels in the aorta and heart continued to increase with the duration of hyperglycaemia. Furthermore, AGE-BSA induced RAGE mRNA expression of human umbilical vein endothelial cells in vitro. Taken together, the AGE accumulation might initiate diabetic macroangiopathy through RAGE, and the increase of RAGE expression by endothelial cells could be a reason that diabetes mellitus accelerates atherosclerosis rapidly.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797717      PMCID: PMC3230864     

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  10 in total

1.  Advanced glycation end products promote proliferation of cardiac fibroblasts by upregulation of KCa3.1 channels.

Authors:  Li-Mei Zhao; Wei Zhang; Li-Ping Wang; Gui-Rong Li; Xiu-Ling Deng
Journal:  Pflugers Arch       Date:  2012-10-02       Impact factor: 3.657

2.  Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients.

Authors:  K Kiuchi; J Nejima; T Takano; M Ohta; H Hashimoto
Journal:  Heart       Date:  2001-01       Impact factor: 5.994

Review 3.  Approaches to prevention of cardiovascular complications and events in diabetes mellitus.

Authors:  Sergio Coccheri
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.

Authors:  Matthias Oelze; Swenja Kröller-Schön; Philipp Welschof; Thomas Jansen; Michael Hausding; Yuliya Mikhed; Paul Stamm; Michael Mader; Elena Zinßius; Saule Agdauletova; Anna Gottschlich; Sebastian Steven; Eberhard Schulz; Serge P Bottari; Eric Mayoux; Thomas Münzel; Andreas Daiber
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

5.  Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse.

Authors:  Hotimah Masdan Salim; Daiju Fukuda; Shusuke Yagi; Takeshi Soeki; Michio Shimabukuro; Masataka Sata
Journal:  Front Cardiovasc Med       Date:  2016-10-26

6.  The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.

Authors:  Sebastian Steven; Matthias Oelze; Alina Hanf; Swenja Kröller-Schön; Fatemeh Kashani; Siyer Roohani; Philipp Welschof; Maximilian Kopp; Ute Gödtel-Armbrust; Ning Xia; Huige Li; Eberhard Schulz; Karl J Lackner; Leszek Wojnowski; Serge P Bottari; Philip Wenzel; Eric Mayoux; Thomas Münzel; Andreas Daiber
Journal:  Redox Biol       Date:  2017-06-22       Impact factor: 11.799

7.  Investigating the effect of some fluoroquinolones on C-reactive protein levels and ACh-Induced blood pressure reduction deviations after aging of diabetes in STZ-Induced diabetic wistar rats.

Authors:  Hussam M Gharib; Mohammad Y Abajy; Abdulnaser Omaren
Journal:  Heliyon       Date:  2020-04-24

8.  Cathepsin-L ameliorates cardiac hypertrophy through activation of the autophagy-lysosomal dependent protein processing pathways.

Authors:  Mei Sun; Maral Ouzounian; Geoffrey de Couto; Manyin Chen; Ran Yan; Masahiro Fukuoka; Guohua Li; Mark Moon; Youan Liu; Anthony Gramolini; George J Wells; Peter P Liu
Journal:  J Am Heart Assoc       Date:  2013-04-22       Impact factor: 5.501

Review 9.  Antigen-induced immunomodulation in the pathogenesis of atherosclerosis.

Authors:  Natalia Milioti; Alexandra Bermudez-Fajardo; Manuel L Penichet; Ernesto Oviedo-Orta
Journal:  Clin Dev Immunol       Date:  2008

10.  Reduction of advanced-glycation end products levels and inhibition of RAGE signaling decreases rat vascular calcification induced by diabetes.

Authors:  Mathieu R Brodeur; Céline Bouvet; Sonia Bouchard; Simon Moreau; Jeanne Leblond; Denis Deblois; Pierre Moreau
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.